Valuation
- Market cap
- 1,479,605,000
- Revenue TTM
- $0
- Net income TTM
- $-108,680,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.31
Trading
- Volume
- 2,061,900
- Avg volume
- 1,949,604
- Day's range
- $14.31 – $15.16
- Shares out
- 98,509,000
- Stochastic %K
- 89%
- Beta
- 2.57
- Analysts
- Strong Buy
- Price target
- $28.58
Company profile
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of...
Show more
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 212 220 6633
- Website
- https://www.mindmed.co
- Address
- One World Trade Center, Suite 8500, New York, United States
Latest news
No headlines yet.
